![Marc Elia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marc Elia
Président chez
INVIVYD, INC.
Fortune : - $ au 31/05/2026
Profil
Marc W.
Elia is the founder of Nivalis Therapeutics, Inc., founded in 2007, and M28 Capital Management LP, founded in 2012.
Current jobs include Chairman at Invivyd, Inc. since 2022, Independent Director at SQZ Biotechnologies Co. since 2018, and Independent Director at Fractyl Health, Inc. since 2021.
Former jobs include Director at Adimab LLC, Analyst at Bridger Management LLC from 2012 to 2019, and Partner at Bridger Capital LLC from 2012 to 2019.
Education includes an undergraduate degree from Carleton College, conferred in 1998.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INVIVYD, INC. -.--% | 19/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Marc Elia
| Sociétés | Poste | Début |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Directeur/Membre du Conseil | 09/08/2018 |
| FRACTYL HEALTH, INC. | Directeur/Membre du Conseil | 16/06/2021 |
| INVIVYD, INC. | Président | 01/07/2022 |
M28 Capital Management LP
 M28 Capital Management LP Investment ManagersFinance M28 Capital pursues a long/short equity strategy focused on companies in the life sciences and biotechnology sectors. The firm seeks to generate attractive, risk-adjusted returns over the long term, powered by major technological breakthroughs and advances in human health. | Directeur Général | 01/08/2012 |
Anciens postes connus de Marc Elia
| Sociétés | Poste | Fin |
|---|---|---|
Bridger Management LLC
 Bridger Management LLC Investment ManagersFinance Bridger focuses on publicly traded equities, emphasizes fundamental and has a research-oriented stock selection in both long and short investments. The firm manages investment vehicles which seek to generate long-term and superior risk-adjusted total returns. They believe that short positions not only serve as a hedge against volatile market conditions, but also generate profit opportunities for the clients. | Analyst-Equity | 01/09/2019 |
Bridger Capital LLC | Corporate Officer/Principal | 01/09/2019 |
Adimab LLC
 Adimab LLC BiotechnologyHealth Technology Operates as a biologics discovery and engineering company that develops antibody drugs | Directeur/Membre du Conseil | - |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of products for patients with cystic fibrosis | Fondateur | - |
Formation de Marc Elia
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
37
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger focuses on publicly traded equities, emphasizes fundamental and has a research-oriented stock selection in both long and short investments. The firm manages investment vehicles which seek to generate long-term and superior risk-adjusted total returns. They believe that short positions not only serve as a hedge against volatile market conditions, but also generate profit opportunities for the clients. | Finance |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Operates as a biologics discovery and engineering company that develops antibody drugs | Health Technology |
SQZ Biotechnologies Co.
 SQZ Biotechnologies Co. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cell therapies for patients with cancer, infectious diseases and serious conditions | Health Technology |
Carleton College
 Carleton College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bridger Capital LLC | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of products for patients with cystic fibrosis | Health Technology |
Fractyl Health, Inc.
 Fractyl Health, Inc. BiotechnologyHealth Technology Develops and sells therapeutics for metabolic diseases, type 2 diabetes and obesity | Health Technology |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital pursues a long/short equity strategy focused on companies in the life sciences and biotechnology sectors. The firm seeks to generate attractive, risk-adjusted returns over the long term, powered by major technological breakthroughs and advances in human health. | Finance |
Invivyd, Inc.
 Invivyd, Inc. BiotechnologyHealth Technology Develops antibody-based solutions for infectious diseases | Health Technology |
Choisissez Zonebourse 
